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Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including
myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G4A [Ala70Thr]),
and showed extremely low plasma cytidine deaminase activity and gemcitabine clearance. Our results suggest that homozygous *3 is
a major factor causing gemcitabine-mediated severe adverse reactions among the Japanese population.
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Gemcitabine (20,20-difluorodeoxycytidine) is a nucleoside anti-
cancer drug for various solid tumours (Noble and Goa, 1997).
Gemcitabine exerts its cytotoxic effect through phosphorylation by
nucleotide kinases, including the deoxycytidine kinase (DCK),
whereas most of the administered gemcitabine is rapidly degraded
by cytidine deaminase (CDA) into its inactive metabolite,
20,20-difluorodeoxyuridine (Plunkett et al, 1995). Various genetic
variations have recently been reported in human DCK and CDA
genes (Ueno et al, 2007).
Our earlier prospective pharmacogenetic study using 256
Japanese cancer patients treated with gemcitabine-based
chemotherapies revealed that one of the CDA single-nucleotide
polymorphisms (SNPs), CDA*3 (CDA208G4A [Ala70Thr],
rs60369023), showed significant associations with reduced CDA
activity, reduced gemcitabine clearance, increased gemcitabine
area under the concentration–time curve (AUC), and an increased
incidence of severe neutropaenia (Sugiyama et al, 2007). Most
notably, one patient who had developed life-threatening toxicities,
including severe myelosuppression, was found to be homozygous
for CDA*3 (CDA*3/*3), and excessive exposure to gemcitabine was
considered responsible for the severe toxicities (Yonemori et al,
2005; Sugiyama et al, 2007).
Owing to a low allele frequency of CDA*3 (3.7% in the Japanese
population), only one homozygous patient was found in the earlier
study, necessitating further examination. For this purpose, we have
carefully monitored toxicities in gemcitabine-treated patients in
the National Cancer Center Hospital for 4.5 years. Three patients
with life-threatening adverse reactions, including serious myelo-
suppression, were identified, and their CDA genotypes, plasma
CDA activities, and pharmacokinetic parameters (when available)
were determined and compared with those of the earlier cases.
PATIENTS AND METHODS
The ethics committees of the National Cancer Center and the
National Institute of Health Sciences approved this study. Written
informed consent was obtained from each participant. Of 176 and
66 pancreatic cancer patients who received gemcitabine mono-
therapy and gemcitabine-based combination chemotherapies,
respectively, at the National Cancer Center Hospital between 1
September 2003 and 31 March 2008, three showed severe and
prolonged myelosuppression with other complications. Character-
istics of the three patients designated A, B, and C are summarised
in Table 1. All these patients received a 30min intravenous
gemcitabine infusion at an initiation dose of 1000mgm
 2. Patient
A initially received gemcitabine and S-1 combination therapy,
whereas patients B and C were given gemcitabine alone.
Measurement of plasma CDA activity towards gemcitabine and
genotyping of CDA and DCK were carried out in the three patients
as reported earlier (Sugiyama et al, 2007; Kim et al, 2008). After
recovery from severe adverse reactions, chemotherapy was
resumed in two patients: patient A received gemcitabine mono-
therapy instead of gemcitabine plus S-1, whereas the gemcitabine
dose was reduced in patient C. Gemcitabine was not resumed in
patient B because of disease progression. Pharmacokinetics were
carried out when 1000 and 450mgm
 2 of gemcitabine were
administered to patients A and C, respectively. Blood sampling
schedule and the measurement method of gemcitabine in plasma
were reported earlier (Sugiyama et al, 2007). Pharmacokinetic
parameters were estimated using WinNonlin ver 4.01 (Pharsight
Corporation, Mountain View, CA, USA).
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Although 30 patients (about 12.4%) among the 242 developed
grade 4 neutropaenia, the toxicity was transient and required no
supportive treatment in most patients except in patients A, B, and
C. Pretreatment organ functions, including bone marrow, renal,
and hepatic functions, were preserved in the three patients
(Table 1). Observed toxicities in the patients are summarised in
Table 2. The serious haematotoxicities requiring intensive
supportive treatments during hospitalisation were recognised in
these patients: patient A was treated with antibiotics because of
febrile neutropaenia, patient B received a platelet transfusion,
and patient C received a red blood cell transfusion, a platelet
transfusion, and a granulocyte colony-stimulating factor. Both the
neutrophil and platelet nadir appeared at approximately day 15 of
the first course of treatment in patients A and B, whereas in patient
C, the nadir occurred on day 15 of the second course of treatment
that was resumed after reducing the dose of gemcitabine. The
symptomatic non-haematologic toxicities shown in Table 2
appeared before severe myelosuppression.
Patients B and C were found to be CDA*3/*3, whereas patient
A did not have CDA*3 (Table 2). No SNPs of DCK, including
DCK364C4T (Pro122Ser), which were reported to have reduced
enzymatic activity (Lamba et al, 2007), were identified in our
three patients. Plasma CDA activities of patients A, B, and C were
compared with those of 121 patients in our earlier study (Sugiyama
et al, 2007) (Figure 1A). Patient A without CDA*3 showed
relatively high plasma CDA activity, whereas plasma CDA activities
in the CDA*3/*3 patients (patients B and C) were comparably low
to those in the earlier reported CDA*3/*3 patient.
Pharmacokinetic parameters of patients A and C were also
shown in Table 2, and their gemcitabine clearances were compared
with those of the earlier reported 250 patients (Sugiyama et al,
2007) (Figure 1B). Although the gemcitabine dose for patient C was
low (450mgm
 2), her gemcitabine AUC was higher than the
average value in the CDA*3-negative patients who were adminis-
tered 1000mgm
 2 gemcitabine. When it was assumed that patient
Table 1 Patient characteristics at baseline
Patient A Patient B Patient C
Sex Female Male Female
Age (years) 57 70 70
Performance status 1 2 1
Stage
a IV IV IV
Previous treatment Surgery None None
Body surface area (m
2) 1.3 1.9 1.1
Laboratory data
Leukocyte (mm
 3) 6300 9700 4300
Neutrophil (mm
 3) 4200 6400 2700
Haemoglobin (gdl
 1) 12.4 16.0 10.8
Platelet (mm
 3) 116000 163000 185000
Total bilirubin (mgdl
 1) 0.6 1.4 0.8
ALT (IUl
 1)2 6 3 5 2 4
Creatinine (mgdl
 1) 0.6 1.2 0.4
Initial regimen Gemcitabine+S-1
b Gemcitabine
alone
Gemcitabine
alone
ALT¼alanine aminotransferase.
aUICC sixth edition.
bAn oral product containing
tegafur, gimeracil, and oteracil potassium.
Table 2 Toxicities, treatment, genotype, and PK analysis
Patient A Patient B Patient C
Grade Value Grade Value Grade Value
Haematologic toxicities
a
Leukocyte (mm
 3) 4 800 3 1100 3 1000
Neutrophil (mm
 3) 4 200 4 300 4 100
Haemoglobin (gdl
 1) 2 8.1 1 13.2 4 6.3
Platelet (mm
 3) 3 26000 4 10000 3 28000
Non-haematologic toxicity
a
Fatigue 2 3 2
Anorexia 3 3 2
Diarrhoea 3 0 1
Stomatitis 3 0 0
Rash 2 0 2
Febrile neutropaenia 3 0 0
Treatment
Resumption of chemotherapy Yes No Yes
Total number of gemcitabine doses 10 2 10
Final dose (mgm
 2) 600 1000 270
Genotype
CDA haplotype
b *1a/*1j *3a/*3a *3a/*3a
DCK haplotype
c *1a/*1a *1a/*1a *1a/*1a
PK analysis
Regimen at PK study Gemcitabine alone Gemcitabine alone
Dose of gemcitabine (mgm
 2) 1000 450
Cmax (mgl
 1) 29.0 Not available 22.5 (49.7
d)
AUC (mghl
 1) 16.2 26.8 (59.0
d)
Clearance (lh
 1m
 2) 61.8 16.6
AUC¼area under the concentration–time curve; Cmax¼maximum plasma concentration; CDA¼cytidine deaminase; DCK¼deoxycytidine kinase; PK¼pharmacokinetics.
aToxicities were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
bCDA haplotype was reported earlier in
Sugiyama et al (2007).
cDCA haplotype was reported earlier in Kim et al (2008).
dOn the basis of the assumption that patient C received 1000mgm
 2 of gemcitabine.
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 2 of gemcitabine, Cmax and AUC values
similar to those observed in the earlier reported CDA*3/*3 patient
were obtained. The value of gemcitabine clearance in patient C
(CDA*3/*3) was less than one-fifth of the median value obtained
earlier from CDA*3-negative patients. The clearance observed in
patient A, who did not have CDA*3, was within the range obtained
earlier from patients without CDA*3 (Figures 1B).
DISCUSSION
We found two (patients B and C) of the three patients who
experienced life-threatening adverse reactions to be homozygous
for CDA*3 and to have an extremely low CDA activity. Taken
together with our earlier observations (Yonemori et al, 2005;
Sugiyama et al, 2007), these life-threatening adverse reactions
appear to have been caused by reduced deamination activity of
CDA because of CDA*3/*3 homozygosity. Sustained plasma
gemcitabine elevations are most likely responsible for these severe
adverse reactions. To date, we have had three CDA*3/*3 patients,
including one reported earlier (Yonemori et al, 2005; Sugiyama
et al, 2007), and all experienced life-threatening severe adverse
reactions. As genotyping of CDA was not carried out in the
remaining 239 patients, we may have overlooked patients with
CDA*3/*3 who did not develop severe toxicities in this study.
However, as the frequency of homozygous CDA*3 in the Japanese
population was estimated to be 0.14% in an earlier study
(Sugiyama et al, 2007), the possibility of missing any such patients
would be very low. Thus, CDA*3/*3 is a potentially important
biomarker for Japanese patients and for at least one African ethnic
group (Fukunaga et al, 2004) for predicting severe gemcitabine-
mediated adverse reactions including myelotoxicities.
We do not have sufficient pharmacokinetic data on CDA*3/*3 to
determine the optimal dose for this fraction of the patient
population. However, the clearance and AUC values for the earlier
reported patient (Sugiyama et al, 2007) and for patient C
(dose adjusted), and the final dose for patient C (270mgm
 2)
suggest that a 75% reduction in the gemcitabine dose, at treatment
initiation, may be appropriate for CDA*3/*3 patients.
Patient A was given combined chemotherapy with oral S-1
(Table 1). As she could not tolerate gemcitabine monotherapy at
the standard dose as shown in Table 2, gemcitabine itself appears
to have been responsible for the life-threatening toxicities in this
patient. Her gemcitabine clearance was within the range observed
in patients without CDA*3 (Sugiyama et al, 2007). Therefore,
we concluded that there was no involvement of altered CDA
activity in the severe neutropaenia experienced by patient A.
Further investigation of gemcitabine pathway genotypes is needed
to clarify factors contributing to this patient’s adverse reactions.
In conclusion, in the Japanese population, CDA*3/*3 is a
major cause of gemcitabine-mediated life-threatening adverse
reactions including myelosuppression. A substantial gemcitabine
dose reduction is necessary for patients who are homozygous
for CDA*3.
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Figure 1 Effects of CDA*3 on (A) plasma CDA activity towards gemcitabine and (B) gemcitabine clearance. The data obtained earlier (Sugiyama et al,
2007) are expressed as open diamonds, and those obtained in this study are as closed symbols. A, B, and C represent patients A, B, and C, respectively. Lines
represent median values for non-*3/non-*3 patients and *3/non-*3 patients.
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